Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fitscha

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
European Journal of Clinical Pharmacology|January 1, 1992
Isradipine improves platelet function in hypertensivesH Sinzinger, I Virgolini, F Rauscha, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|March 1, 1994
Isradipine inhibits mitotic and proliferative activity in the arterial wallP Fitscha, F Rauscha, J O'Grady, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1989
Evidence for 20 mg aspirin (ASA) as being optimalH Sinzinger, I Virgolini, R Eyb, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1989
Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: a placebo controlled double-blind trialI Virgolini, P Fitscha, J O'Grady, et al.
British Journal of Clinical Pharmacology|January 1, 1982
Effects of age and smoking on the pharmacokinetics of pindolol and propranololG Hitzenberger, P Fitscha, T Beveridge, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|April 1, 1992
The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibitionP Fitscha, A Keiler, F Rauscha, et al.
Thrombosis Research|February 1, 1992
Modification of platelet function by isosorbide dinitrate in patients with coronary artery diseaseH Sinzinger, I Virgolini, J O'Grady, et al.
Lancet (London, England)|July 19, 1986
Prostaglandin E1 decreases activation of arterial smooth-muscle cellsH Sinzinger, P Fitscha, O Wagner, et al.
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1988
Platelet derived growth factor (PDGF) and prostaglandins (PGE1, PGI2) as modulators of the atherogenetic processH Sinzinger, T Zidek, P Fitscha, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1984
Follow-up of in-vivo platelet function (platelet half-life, thromboxane B2) in patients with coronary heart diseaseP Fitscha, J Kaliman, H Sinzinger, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
European Journal of Clinical Pharmacology|January 1, 1992
Isradipine improves platelet function in hypertensivesH Sinzinger, I Virgolini, F Rauscha, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|March 1, 1994
Isradipine inhibits mitotic and proliferative activity in the arterial wallP Fitscha, F Rauscha, J O'Grady, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1989
Evidence for 20 mg aspirin (ASA) as being optimalH Sinzinger, I Virgolini, R Eyb, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1989
Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: a placebo controlled double-blind trialI Virgolini, P Fitscha, J O'Grady, et al.
British Journal of Clinical Pharmacology|January 1, 1982
Effects of age and smoking on the pharmacokinetics of pindolol and propranololG Hitzenberger, P Fitscha, T Beveridge, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|April 1, 1992
The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibitionP Fitscha, A Keiler, F Rauscha, et al.
Thrombosis Research|February 1, 1992
Modification of platelet function by isosorbide dinitrate in patients with coronary artery diseaseH Sinzinger, I Virgolini, J O'Grady, et al.
Lancet (London, England)|July 19, 1986
Prostaglandin E1 decreases activation of arterial smooth-muscle cellsH Sinzinger, P Fitscha, O Wagner, et al.
Folia Haematologica (Leipzig, Germany : 1928)|January 1, 1988
Platelet derived growth factor (PDGF) and prostaglandins (PGE1, PGI2) as modulators of the atherogenetic processH Sinzinger, T Zidek, P Fitscha, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1984
Follow-up of in-vivo platelet function (platelet half-life, thromboxane B2) in patients with coronary heart diseaseP Fitscha, J Kaliman, H Sinzinger, et al.
Pageof 13